Drug-use review program for concurrent histamine H2-receptor antagonist-sucralfate therapy.
Loading...
Issue Date
1990-09
Authors
Kane, Michael P
Briceland, Laurie L
Garris, R E
Favreau, B N
Degree
Advisor
Committee Members
Journal Title
Journal ISSN
Volume Title
Abstract
The effect of drug-use review on concomitant histamine H2-receptor antagonist-sucralfate therapy at a 600-bed, university-affiliated Veterans Affairs medical center was studied. In an effort to curtail the concomitant use of H2-antagonist plus sucralfate therapy, the department of pharmacy, in conjunction with the gastroenterology service, developed and introduced criteria for the appropriate use of combination therapy. The extent of prescribing of concomitant histamine H2-receptor antagonist-sucralfate therapy before and after implementation of criteria-based guidelines and the appropriateness of current H2-receptor antagonist-sucralfate combination therapy, based on the guidelines, were assessed. The effectiveness of the intervention process was evaluated, and cost savings associated with intervention were calculated. After intervention, the number of treatment courses of histamine H2-receptor antagonist-sucralfate combination therapy decreased by 30%. However, of the 109 evaluable postintervention combination treatment courses, only one complied with both the indication and the duration of treatment criteria. This review of prescribing patterns and the implementation of criteria-based guidelines proved an effective means of reducing inappropriate combination therapy and resulted in annual cost savings of $25,000.
Citation
Kane MP, Briceland LL, Garris RE, Favreau BN. Drug-use review program for concurrent histamine H2-receptor antagonist-sucralfate therapy. Am J Hosp Pharm. 1990 Sep;47(9):2007-10. PMID: 1977317.
ACPHS Research Commons URI
Description
Click on the Resource Link to access the article (may not be free).